Impact of second-generation transoral incisionless fundoplication on atypical GERD symptoms: a systematic review and meta-analysis

Background and Aims: Transoral incisionless fundoplication (TIF) using the EsophyX device (EndoGastric So-lutions, Inc, Redmond, Wash, USA) is a minimally invasive endoscopic fundoplication technique. Our study aimed to assess the efficacy of TIF for atypical GERD symptoms in patients with chronic or refractory GERD. Methods: A systematic search of 4 major databases was performed. All original studies assessing atypical GERD using a validated symptom questionnaire (the reflux symptom index [RSI]) were included. The RSI score was as-sessed before and after TIF at a 6-and 12-month follow-up. Data on technical success rate, adverse events, proton pump inhibitor (PPI) use, and patient satisfaction were also collected. Only TIF procedures currently in practice using the EsophyX device (ie, TIF 2.0) and TIF with concomitant hiatal hernia repair were included in the review. Results: Ten studies (564 patients) were included. At the 6-and 12-month follow-up, there was a mean reduction of 15.72 (95% confidence interval, 12.15-19.29) and 14.73 (95% confidence interval, 11.74-17.72) points, respec-tively, in the RSI score post-TIF, with a technical success rate of 99.5% and a pooled adverse event rate of 1%. At both time intervals, more than two-thirds of the patients were satisfied with their health condition and roughly three-fourths of the patients were off daily PPIs. Conclusions: Our study shows that TIF using the EsophyX device is safe and effective in reducing atypical GERD symptoms at 6 and 12 months of follow-up. It improves patient-centered outcomes and can be a minimally inva-sive therapeutic option for patients suffering from atypical GERD symptoms on chronic medical therapy. (Gastro-intest Endosc 2023;97:394-406.)

Automated summary

This study assessed the efficacy of transoral incisionless fundoplication (TIF) using the EsophyX device in treating atypical GERD symptoms. The results showed that TIF can effectively reduce these symptoms at 6 and 12 months of follow-up, with a high technical success rate and low adverse event rate. Most patients were satisfied with their health condition and a majority of them were able to stop using daily PPIs.